Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Lap/Epi in HER2-positive, Topoisomerase II alpha-positive metastatic breast cancer
2011-005002-30Phase 2Terminated
- Sponsor
- Cancer Trials Ireland
- Start
- Nov 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib and epirubicin in breast cancer, sponsored by Cancer Trials Ireland. Primary endpoint: Overall Response Rate. Started Nov 2011; status: terminated.
02
Drugs
lapatinibepirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-005002-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005002-30.